Jan van de Winkel, Genmab CEO

Q&A: Gen­mab CEO on ink­ing the first ac­qui­si­tion in the com­pa­ny's 25-year his­to­ry

Gen­mab is an un­usu­al com­pa­ny in phar­ma. In 25 years, it has 44 INDs — 20 of those are still in clin­i­cal de­vel­op­ment — and eight mar­ket­ed med­i­cines. Un­til Wednes­day’s $1.8 bil­lion deal for an­ti­body-drug con­ju­gate mak­er Pro­found­Bio, it had nev­er done a takeover.

But it’s not the drug­mak­er’s first go with AD­Cs. Gen­mab mar­kets Tiv­dak with Pfiz­er, by way of the phar­ma gi­ant’s ac­qui­si­tion of Seagen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.